在第78届美国糖尿病协会(ADA)科学年会上披露有效性、依从性和持续性得到改善的数据
- 6个月:-1.10%(Trulicity®度拉糖肽),-0.86%(利拉鲁肽)
- 1年:-0.98%(Trulicity®度拉糖肽),-0.77%(利拉鲁肽)
- 6个月:-1.15%(Trulicity®度拉糖肽),-0.92%(艾塞那肽QW)
- 1年:-1.00%(Trulicity®度拉糖肽),-0.77%(艾塞那肽QW)
Trulicity®(度拉糖肽) vs.利拉鲁肽
- 依从性:51.2%(Trulicity®度拉糖肽),38.2%(利拉鲁肽)
- 持续性:252.8天(Trulicity®度拉糖肽),218.2天(利拉鲁肽)
- 中止治疗的患者:45.0%(Trulicity®度拉糖肽),56.2%(利拉鲁肽)
Trulicity®(度拉糖肽)vs.艾塞那肽QW
- 依从性:50.7%(Trulicity®度拉糖肽),31.9%(艾塞那肽QW)
- 持续性:251.4天(Trulicity®度拉糖肽),192.5天(艾塞那肽QW)
- 中止治疗的患者:45.1%(Trulicity®度拉糖肽),65.6%(艾塞那肽QW)
关于本文中的研究
度拉糖肽已在中国递交上市申请,并已进入药审中心优先审评
5,目前还未上市。参考文献
1. Mody R, Huang Q, Yu M, et. al. Comparative Glycemic Effectiveness of Dulaglutide vs. Liraglutide and Exenatide QW in a US Real-World Setting. Abstract 1071-P. Presented at 78thAmerican Diabetes Association Scientific Sessions; June 22-26, Orlando, FL.
2. Mody R, Huang Q, Yu M, et. al. Dulaglutide has Higher Adherence and Persistence than Liraglutide and Exenatide QW: 1-year Follow-up from US Real-World Data. Abstract 1264-P. Presented at 78thAmerican Diabetes Association Scientific Sessions; June 22-26, Orlando, FL.
3. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Available at: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. November 2017.
4. International Diabetes Federation. IDF Diabetes Atlas, 8th edn, 2017. Available at: http://www.diabetesatlas.org/. November 2017.
5. http://www.cde.org.cn/news.do?method=changePage&pageName=service&frameStr=21
閱讀更多 美通社 的文章